Sable Bio

Investor: MMC Ventures

Sable Bio, a London-based AI drug safety startup, has successfully raised £2.8 million in seed funding, with MMC Ventures leading the investment round.Summary of transaction details:Value: £2.8 millionSector: Healthcare & Biotech (AI Drug Safety)Advisor: Not mentionedKey Entities: Sable Bio (Target), MMC Ventures (Lead Investor)Location: London, UKNote: This funding will be instrumental in scaling Sable Bio's platform, which aids pharmaceutical companies in identifying safety risks earlier in the drug discovery process, thereby improving efficiency and patient outcomes.

Investor: Episode1 Ventures, Seedcamp